Immune Support / Level A / FDA Approved / Last reviewed 2026-08-27

Motixafortide Evidence Guide

Motixafortide (Aphexda) is FDA-approved in combination with G-CSF for hematopoietic stem cell mobilization prior to autologous transplantation in multiple myeloma. The Phase 3 GENESIS trial showed significantly more CD34+ cells mobilized with fewer apheresis sessions versus G-CSF alone. A well-evidenced stem cell mobilization enhancer for a specific transplant medicine context.

Our Take

Evidence context: Hematopoietic stem cell mobilization (multiple myeloma transplant), CXCR4 antagonist pharmacology
Evidence grade: Level A
Confidence: High
Reference context: Regulatory label reference: 1.25mg/kg subcutaneous 10-14 hours before each apheresis session

Benefits and Evidence

Stem Cell Mobilization: Level A, includes human evidence - Phase 3 GENESIS trial demonstrated that motixafortide + G-CSF enabled 92% of patients to reach target CD34+ cell count of >=6 x10^6 cells/kg in <=2 apheresis sessions, vs 26% with placebo + G-CSF.
Engraftment Success: Level A, includes human evidence - Patients transplanted with motixafortide-mobilized grafts showed successful neutrophil and platelet engraftment comparable to standard mobilization approaches.
Injection Site Reactions: Level A, includes human evidence - Injection site reactions including erythema, pain, and pruritus occurred in approximately 56% of patients but were generally mild to moderate.

Side Effects and Warnings

Injection site reactions (erythema, pain, pruritus)
Diarrhea
Musculoskeletal pain
Dizziness
Nausea
Hypersensitivity reactions
Anaphylaxis and serious hypersensitivity reactions reported - observe for at least 1 hour after injection
Splenic enlargement/rupture possible with G-CSF combination

Research Dosage References

<strong>Subcutaneous injection</strong> - 1.25 mg/kg - Single dose on day of apheresis - Administered after G-CSF priming (typically 4 days of G-CSF before motixafortide). Given on the morning of planned apheresis, approximately 10 hours before collection.

Mechanism of Action

Motixafortide mobilizes stem cells through CXCR4 receptor antagonism: 1. CXCR4 high-affinity antagonism: Binds to and blocks CXCR4 receptors on hematopoietic stem and progenitor cells with high affinity and slow off-rate kinetics. 2. CXCL12/SDF-1 axis disruption: Blocks the interaction between CXCR4 on stem cells and CXCL12 (stromal cell-derived factor 1) expressed by bone marrow stromal cells, releasing stem cells from the marrow niche. 3. Rapid mobilization: When combined with G-CSF, produces rapid and robust mobilization of CD34+ hematopoietic stem cells into peripheral blood within hours. 4. Enhanced collection: Increases the yield of CD34+ cells during apheresis, often achieving target cell counts in fewer collection sessions.

Legal Status

FDA-approved (September 2023) in combination with G-CSF for mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma. Available by prescription only. Marketed as Aphexda by BioLineRx.

Primary Sources

Motixafortide and G-CSF for stem cell mobilization in multiple myeloma (GENESIS). N Engl J Med, 2023.
BL-8040 (motixafortide): a novel CXCR4 antagonist for stem cell mobilization. Clin Cancer Res, 2019.

Quick Answers

Where is the strongest evidence for Motixafortide?

What are the main side effects of Motixafortide?

Motixafortide side effects and warning signals include Injection site reactions (erythema, pain, pruritus), Diarrhea, Musculoskeletal pain, Dizziness, and Nausea.

What evidence level is Motixafortide?

Motixafortide is rated Level A; the listed research status is FDA Approved.